An influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying sales could reach $7.7 billion in 2022.
NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft
NICE has recommended regular NHS funding for Roche’s immunotherapy Tecentriq (atezolizumab) in tough-to-treat advanced triple negative breast cancer in final draft guidance, after a previou
Martin Shkreli, the pharma CEO once branded as America’s most hated man has been denied release from prison after a judge ruled his plan to save the world from coronavirus was “delusional”.
No-one even knows if it is possible to make a vaccine against COVID-19 and already there is an escalating row about cost and equitable access if one succeeds in clinical trials.